TY  - JOUR
AU  - López Millán, Belén
AU  - Costales, Paula
AU  - Gutiérrez Agüera, Francisco
AU  - Díaz de la Guardia, Rafael
AU  - Roca Ho, Heleia
AU  - Vinyoles, Meritxell
AU  - Rubio Gayarre, Alba
AU  - Safi, Rémi
AU  - Castaño, Julio
AU  - Romecín, Paola Alejandra
AU  - Ramirez Orellana, Manuel
AU  - Anguita Mandly, Eduardo Luis
AU  - Jeremías, Irmela
AU  - Zamora, Lurdes
AU  - Rodríguez Manzaneque, Juan Carlos
AU  - Bueno, Clara
AU  - Morís, Francisco
AU  - Menéndez, Pablo
PY  - 2022
DO  - 10.3390/cancers14061593
SN  - 2072-6694
UR  - https://hdl.handle.net/20.500.14352/71621
T2  - Cancers
AB  - Patients with AML harboring constitutively active mutations in the FLT3 receptor generally have a poor prognosis (FLT3-ITDMUT). Despite the fact that several FLT3 inhibitors have been developed, clinical responses are commonly partial or not durable,...
LA  - eng
M2  - 1593
PB  - MPDI
KW  - AML
KW  - EC-70124 multi-kinase inhibitor
KW  - FLT3-ITD mutation
KW  - FLT3 inhibitor
KW  - AML preclinical model
TI  - The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
TY  - journal article
VL  - 14
ER  -